Cargando…

Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies

BACKGROUND AND OBJECTIVES: In a proportion of patients, dementia with Lewy bodies (DLB) is associated with Alzheimer disease (AD) copathology, which is linked to accelerated cognitive decline and more extensive cortical atrophy. The objective was to evaluate the relationship between a biomarker of A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alam, John J., Maruff, Paul, Doctrow, Susan R., Chu, Hui-May, Conway, Jennifer, Gomperts, Stephen N., Teunissen, Charlotte
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624490/ https://www.ncbi.nlm.nih.gov/pubmed/37657939 http://dx.doi.org/10.1212/WNL.0000000000207755

Ejemplares similares

Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration
por: Jiang, Ying, et al.
Publicado: (2022)

Neflamapimod induces vasodilation in resistance mesenteric arteries by inhibiting p38 MAPKα and downstream Hsp27 phosphorylation
por: Pandey, Ajay K., et al.
Publicado: (2022)

Longitudinal Tau Positron Emission Tomography in Dementia with Lewy Bodies
por: Chen, Qin, et al.
Publicado: (2022)

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

Quantifying regional α ‐synuclein, amyloid β, and tau accumulation in lewy body dementia
por: Miller, Rebecca L., et al.
Publicado: (2022)

Lewy body disease and dementia with Lewy bodies
por: KOSAKA, Kenji
Publicado: (2014)

A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease
por: Prins, Niels D., et al.
Publicado: (2021)

Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression
por: van de Beek, Marleen, et al.
Publicado: (2020)

Dementia with Lewy bodies
por: McKeith, Ian
Publicado: (2004)

VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders
por: Irwin, David J., et al.
Publicado: (2018)

The combined effect of amyloid-β and tau biomarkers on brain atrophy in dementia with Lewy bodies
por: Abdelnour, Carla, et al.
Publicado: (2020)

Research criteria for the diagnosis of prodromal dementia with Lewy bodies
por: McKeith, Ian G., et al.
Publicado: (2020)

Altered Expression of Human Mitochondrial Branched Chain Aminotransferase in Dementia with Lewy Bodies and Vascular Dementia
por: Ashby, Emma L., et al.
Publicado: (2016)

Neuroimaging in Lewy body dementia
por: Yousaf, Tayyabah, et al.
Publicado: (2018)

Microbleeds in dementia with Lewy bodies
por: Donaghy, Paul C., et al.
Publicado: (2020)

Advances in dementia with Lewy bodies
por: Armstrong, Melissa J.
Publicado: (2021)

Neuroimaging in Dementia With Lewy Bodies
por: Saha, Abhishikta, et al.
Publicado: (2021)

Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies
por: van der Lee, Sven J., et al.
Publicado: (2021)

Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium
por: Scott, Gregory D., et al.
Publicado: (2022)

AV‐1451 tau and β‐amyloid positron emission tomography imaging in dementia with Lewy bodies
por: Kantarci, Kejal, et al.
Publicado: (2016)

A soluble tau fragment generated by caspase-2 is associated with dementia in Lewy body disease
por: Smith, Benjamin R., et al.
Publicado: (2019)

Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study
por: Wolters, E.E., et al.
Publicado: (2020)

α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2018)

Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies
por: van de Beek, M., et al.
Publicado: (2020)

Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease
por: Hall, Sara, et al.
Publicado: (2020)

Cognitive profile in prodromal dementia with Lewy bodies
por: Kemp, Jennifer, et al.
Publicado: (2017)

Neuroimaging characteristics of dementia with Lewy bodies
por: Mak, Elijah, et al.
Publicado: (2014)

Comprehensive treatment of dementia with Lewy bodies
por: Boot, Brendon P
Publicado: (2015)

Neurophysiological biomarkers for Lewy body dementias
por: Cromarty, Ruth A., et al.
Publicado: (2016)

Exome sequencing in dementia with Lewy bodies
por: Keogh, M J, et al.
Publicado: (2016)

Clinical prevalence of Lewy body dementia
por: Kane, Joseph P. M., et al.
Publicado: (2018)

Dementia with Lewy bodies: an update and outlook
por: Outeiro, Tiago Fleming, et al.
Publicado: (2019)

Young-Onset Dementia with Lewy Bodies
por: Aiba, Yosuke, et al.
Publicado: (2018)

Pharmacological Management of Dementia with Lewy Bodies
por: Hershey, Linda A., et al.
Publicado: (2019)

Spatial Perseveration in Dementia with Lewy Bodies
por: Assal, Frédéric, et al.
Publicado: (2007)

Clinical diagnosis of Lewy body dementia
por: Surendranathan, Ajenthan, et al.
Publicado: (2020)

Gut microbiota in dementia with Lewy bodies
por: Nishiwaki, Hiroshi, et al.
Publicado: (2022)

Onset matters in dementia with Lewy bodies
por: Müller, Sebastian Johannes, et al.
Publicado: (2023)

Improving the clinical detection of Lewy body dementia with the Lewy body composite risk score
por: Galvin, James E.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qeaaflatnsgr364pdibn0qfjo2